Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

Vertex Pharmaceuticals, a cystic fibrosis powerhouse, is sprinting into new medical territories with big ambitions. The ...

Despite recent market volatility, buying shares of top companies that can at least match average returns through 2035 -- or ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Data presented at ATS 2025 showed that lung improvement in paediatric cystic fibrosis (CF) patients receiving ETI therapy is ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.